about
No effect on pharmacokinetics of tamoxifen and 4-hydroxytamoxifen by multiple doses of red clover capsule in ratsComparative assessment of bioanalytical method validation guidelines for pharmaceutical industry.DBS-platform for biomonitoring and toxicokinetics of toxicants: proof of concept using LC-MS/MS analysis of fipronil and its metabolites in blood.Bioanalysis of antitubercular drugs using liquid chromatography.Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases.Synthesis and Evaluation of Chirally Defined Side Chain Variants of 7-Chloro-4-Aminoquinoline To Overcome Drug Resistance in Malaria Chemotherapy.Species differences between rat and human in vitro metabolite profile, in vivo predicted clearance, CYP450 inhibition and CYP450 isoforms that metabolize benzanthrone: Implications in risk assessment.Development and validation of UPLC-MS/MS assay for quantification of cladrin: Absolute bioavailability and dose proportionality study in rats.Pharmacological activation of aldehyde dehydrogenase 2 promotes osteoblast differentiation via bone morphogenetic protein-2 and induces bone anabolic effect.Identification of novel β-lactams and pyrrolidinone derivatives as selective Histamine-3 receptor (H3R) modulators as possible anti-obesity agents.Preparation and in-vitro/in-vivo characterization of trans-resveratrol nanocrystals for oral administration.Skeletal restoration by phosphodiesterase 5 inhibitors in osteopenic mice: Evidence of osteoanabolic and osteoangiogenic effects of the drugsMechanistic exploration of quercetin against metronidazole induced neurotoxicity in rats: Possible role of nitric oxide isoforms and inflammatory cytokinesCorrigendum to "Identification of novel β-lactams and pyrrolidinone derivatives as selective Histamine-3 receptor (H3R) modulators as possible anti-obesity agents" [Eur. J. Med. Chem. 152 (2018) 148-159]LC-ESI-MS/MS method for the simultaneous determination of isoformononetin, daidzein, and equol in rat plasma: Application to a preclinical pharmacokinetic studyBioavailability Enhancement of Poorly Soluble Drugs: The Holy Grail in Pharma IndustryBioavailability, tissue distribution and excretion studies of a potential anti-osteoporotic agent, medicarpin, in female rats using validated LC-MS/MS methodSynthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral LeishmaniasisOral dosing of pentoxifylline, a pan-phosphodiesterase inhibitor restores bone mass and quality in osteopenic rabbits by an osteogenic mechanism: A comparative study with human parathyroid hormoneNeuropharmacokinetics: a bridging tool between CNS drug development and therapeutic outcomeReversal of Osteopenia in Ovariectomized Rats by Pentoxifylline: Evidence of Osteogenic and Osteo-Angiogenic Roles of the DrugNovel Tetrahydroquinazolinamines as Selective Histamine 3 Receptor Antagonists for the Treatment of Obesityβ-Amino acid derivatives as mitochondrial complex III inhibitors of L. donovani: A promising chemotype targeting visceral leishmaniasisChronic histamine 3 receptor antagonism alleviates depression like conditions in mice via modulation of brain-derived neurotrophic factor and hypothalamus-pituitary adrenal axis
P50
Q36245924-1DA0D9D6-6262-48FD-94EA-1D1DF5D3B4E5Q38834420-76C97525-3995-4B64-9944-67A93E27497DQ38890687-33B82F1E-4475-470A-8D6B-FE27665CA311Q39036444-5AC7E73D-7541-48D3-B65A-575B07491A4AQ39154898-D8160AD4-C55F-4EE6-9827-F2C0A8877252Q41775488-2206866D-739D-4055-B2CA-D67C64AFC800Q46263707-4E5BF6D0-71CA-4157-BB50-D7E3B41DD3C4Q49901806-FC4440F3-A1DF-44DC-AB44-0A2BD09D30AFQ51236768-5C502AB3-979B-4298-821B-652171605FFDQ52716019-656FEE57-4A21-4685-88B0-D7E5CB89922CQ52790753-50E4AAD6-AF0D-4693-986A-C0C714B4F128Q89999591-9FCF9925-3F4D-4E1B-8AE6-678C644C6BAAQ90165723-58032F25-5674-4600-8F14-7AC2E8B62D0AQ90385751-2CB58BA1-020F-4918-8B49-87FB45950A05Q90819113-213FF280-ADF3-47F3-9264-6FC00E360DEEQ91301945-01DF46F1-3D9C-4189-9FB7-2689A0B05E5EQ92121112-DE766FDB-A7CB-4155-9309-5F32F1B76B99Q92265975-3F27F77A-8281-4FBE-972D-3702DD032DE1Q92281898-3FA44CA3-36CA-4977-9050-4116DF62AF70Q92535882-0557ED91-3E92-407F-B43F-CEB15CEB7A71Q92596834-E7F72495-9026-489C-994D-BA394A115865Q93175442-CCB9F4A6-953E-4671-B8BB-49E4319A598DQ93199039-2F309E78-DEB2-4D63-903E-BAB6DE173DDBQ93242723-9C9B45CC-E5E7-4DBD-AC89-8891EE50B654
P50
description
investigador
@es
researcher
@en
name
Mamunur Rashid
@en
type
label
Mamunur Rashid
@en
prefLabel
Mamunur Rashid
@en
P31
P496
0000-0003-3122-2784